Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Everolimus: A classical mammalian target of rapamycin inhibitor?
Howard Eisen
Department of Medicine
Penn State Heart and Vascular Institute
Division of Cardiology
Research output
:
Contribution to journal
›
Review article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Everolimus: A classical mammalian target of rapamycin inhibitor?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
MTOR Inhibitor
100%
Everolimus
100%
Renal Function
44%
Cyclosporine
33%
Cardiac Allograft Vasculopathy
33%
Clinical Trials
22%
Cytomegalovirus Infection
22%
Mammalian Target of Rapamycin (mTOR)
22%
Reduced Dose
22%
Cardiac Allograft Rejection
22%
Clinical Application
11%
Pivotal Trial
11%
Clinical Practice
11%
Clinical Experience
11%
Recent Experience
11%
Adverse Events
11%
Calcineurin Inhibitors
11%
Cardiac Allograft
11%
Clinical Observation
11%
Hypertriglyceridemia
11%
European Countries
11%
Cardiac Transplantation
11%
Immunosuppressive Agents
11%
Trough Level
11%
Proliferation Signal Inhibitors
11%
Acute Cellular Rejection
11%
Impaired Renal Function
11%
Medicine and Dentistry
Everolimus
100%
Mammalian Target of Rapamycin Inhibitor
100%
Kidney Function
55%
Clinical Trial
33%
Cyclosporine
33%
Cardiac Allograft Vasculopathy
33%
Cytomegalovirus Infection
22%
Mechanistic Target of Rapamycin
22%
Cardiac Graft Rejection
22%
Adverse Event
11%
Heart Graft
11%
Allograft
11%
Immunosuppressive Drug
11%
Acute Graft Rejection
11%
Deterioration
11%
Clinical Observation
11%
Heart Transplantation
11%
Calcineurin Inhibitor
11%
Trough Level
11%
Hypertriglyceridemia
11%
Pharmacology, Toxicology and Pharmaceutical Science
Everolimus
100%
Mammalian Target of Rapamycin Inhibitor
100%
Clinical Trial
33%
Ciclosporin
33%
Cytomegalovirus Infection
22%
Mammalian Target of Rapamycin
22%
Cardiac Graft Rejection
22%
Adverse Event
11%
Immunosuppressive Agent
11%
Calcineurin Inhibitor
11%
Hypertriglyceridemia
11%
Deterioration
11%
Trough Level
11%
Acute Graft Rejection
11%
Immunology and Microbiology
Sirolimus
100%
Everolimus
100%
Kidney Function
55%
Ciclosporin
33%
Cytomegalovirus Infection
22%
Cardiac Graft Rejection
22%
Allograft Vasculopathy
22%
Acute Graft Rejection
11%
Immunosuppressive Drug
11%
Blood Level
11%
Allograft
11%